AMCP Foundation

DATA DRIVERS FOSTERING INNOVATIONS IN ONCOLOGY

9th ANNUAL RESEARCH SYMPOSIUM

October 29, 2019
Gaylord National Resort & Convention Center

AMCP *held in conjunction with* NEXUS2019

Funding Partners

AMGEN MERCK Pfizer

CONTENTS

CONGRATULATIONS, SCHOLARSHIP RECIPIENTS

New practitioners, graduate students, residents, fellows, student pharmacists, patient advocates, researchers, clinicians, or other health care professionals with an established commitment to placing research in practice were invited to apply for scholarships to attend the 2019 Research Symposium. Scholarships were made possible through the support of our funding partners.

Support our efforts to offer immersive educational experiences. Learn more and donate now.

www.amcpfoundation.org

ABOUT AMCP FOUNDATION

Developing leaders. Enhancing health.

The AMCP Foundation is the research, education and philanthropic organization supporting AMCP, the leading professional association in managed care. The AMCP Foundation advances collective knowledge on major issues associated with the practice of pharmacy in managed health care, including its impact on patient outcomes. The Foundation also cultivates future leaders in the field through immersive experiences for student pharmacists, like our National P&T Competition.
www.amcpfoundation.org

AMCP Foundation

ABOUT AMCP

Optimizing medicine. Improving lives.

AMCP is the professional association leading the way to help patients get the medications they need at a cost they can afford. AMCP's diverse membership of pharmacists, physicians, nurses, and professionals in life sciences and biopharmaceutical companies leverage their specialized expertise in clinical evidence and economics to optimize medication benefit design and population health management and help patients access cost-effective and safe medications and other drug therapies. AMCP members improve the lives of nearly 300 million Americans served by private and public health plans, pharmacy benefit management firms, and emerging care models.
www.amcp.org

AMCP

Data Drivers Fostering Innovations in Oncology

Annually our Research Symposium serves as a leading forum for discussing managed care challenges and opportunities in our continually evolving health care system. The Symposium also offers an opportunity to illustrate elements from AMCP Foundation's environmental monitoring series, Trends in Health Care: Disruptors and Opportunities. During today's event, we build upon three of the forcing factors identified in our most recent research: innovative and curative therapies, expedited drug approvals and the role of health IT and artificial intelligence.

Symposium attendees will learn from national experts who will share insights on such things as evolving technologies, new treatment decision paradigms, the use of big data, and innovative ways to address affordability in cancer treatment. Other areas of focus include clinical decision-making in patient care; patients' concerns about health plan and payers' use of data and shared decision-making; and the biopharmaceutical industry's use of health IT and artificial intelligence to advance research, accelerate regulatory approvals and communicate value.

We strongly encourage active participation by Symposium attendees in discussion periods. The ideas and recommendations that emerge will result in identifying future strategies, potential programs, and actions that can help improve the quality of health care delivery and patient outcomes.

Our efforts in informing health care professionals and others about the evolving health care environment began in 1990 when the Foundation was created, and do not end today. The AMCP Foundation is committed to sharing today's findings and continuing to refine this body of knowledge. Please plan to attend our Symposium Highlights webinar January 16, 2020, and look for a Symposium summary to be distributed with a future issue of AMCP's *Journal of Managed Care and Specialty Pharmacy*.

With gratitude, we acknowledge the support of this year's Symposium sponsors Amgen, Merck, and Pfizer (which also continues its support of the AMCP Foundation's Trends in Health Care research).

Paula J. Eichenbrenner, MBA, CAE, Executive Director
Phillip L. Schneider, MA, MS, Senior Consultant, Strategic Initiatives
Ebony S. Clay, PMP, Senior Manager, Programs & Development
Shyra G. Bias, Managed Care Research and Nonprofit Leadership Intern

Funding Partners

AMGEN MERCK Pfizer

AMCP Foundation

AGENDA—OCTOBER 29, 2019

Data Drivers Fostering Innovations in Oncology

1:00 pm

Welcoming Remarks, Symposium Objectives

Paula J. Eichenbrenner, MBA, CAE,
Executive Director, AMCP Foundation

Moderator Perspectives: Aspects of Data Impact on Innovations in Oncology

Peter Wehrwein, Editor-in-Chief,
Managed Care Magazine

1:20

Expedited Drug Approvals Leading to Innovative & Curative Therapies

- ***Trends in Health Care: Expedited Drug Approvals***
  Breanna Popelar, PharmD, MS,
  Assistant Director, Strategic Market Access & Intelligence, Xcenda
- ***The Use of Real-World Endpoints in Cancer Drug Development***
  Jeff Allen, PhD, President and CEO,
  Friends of Cancer Research

1:50

Best Poster Presentation

- Karen L. Rascati, RPh, PhD, Assistant Editor, *Journal of Managed Care and Specialty Pharmacy*
- Michelle Chang, PharmD, MBA, Clinical Director, CVS Health
- ***Treatment Patterns & Outcomes from Linked Claims Plus Clinical Data***
  Stacey DaCosta Byfield, PhD, MPH, Director of Research, UnitedHealth Group Research and Development

2:10

Patient Experiences: Cost of Care, Treatment Research & Survivorship

- ***Access, Affordability and Equity: Impact of Cost of Care and Financial Toxicity***
  Gwen Darien, Executive Vice President for Patient Advocacy and Engagement, National Patient Advocate Foundation
- ***The Importance of Patient Experience Data: From Research to Survivorship***
  Elizabeth Franklin, MSW, Executive Director, Cancer Policy Institute, Cancer Support Community

2:50

Break

3:00

Federal Research: Data Utilization & Innovative Therapies

- ***FDA Perspective on the Use of Real-World Data: Recent Progress and Future Challenges***
  Harpreet Singh, MD, Team Leader, Breast Cancer Drug Development, FDA
- ***Novel and Collaborative Approaches in Oncology RWD: Advancing Cancer Surveillance***
  Donna Rivera, PharmD, MSc, Scientific Project Officer, National Cancer Institute, NIH

3:40

Achieving and Utilizing AI & Health Data's Potential

- ***AI: Achieving and Utilizing its Potential***
  Petra Schultz, PharmD, Associate Chief Health Officer, IBM Watson Health
- ***Revolutionizing Health Care by Individualizing Patient Care***
  Joga Gobburu, PhD, MBA, FCP, Co-founder and Professor Director, Pumas-AI and Univ. MD School of Pharmacy

4:20

Concluding Dialogue: Who Wins, Why & How?

- Peter Wehrwein
- Kim A. Caldwell, RPh, Principal,
  Texas Star Healthcare Consulting, LLC

4:50 – 5:00

Wrap-Up and Next Steps

5:00 – 6:00

AMCP Foundation Reception

AMCP Foundation

BEST POSTER ABSTRACT

Evaluation of Treatment Patterns and Outcomes from Linked Claims plus Clinical Prior Authorization Data in Patients Diagnosed with Triple Negative Breast Cancer (TNBC)

Presenter: Stacey DeCosta, PhD, MPH, Director of Research, UnitedHealth Group Research and Development

Authors: Benjamin Chastek, MS, Lincy Lal, PhD, PharmD, Stephanie Korrer, Stacey Dacosta Byfield, PhD, MPH

Poster Number: C23

Background:

Integration of clinical and claims data allows for the examination of outcomes and characteristics that are not generally available in a single database, and is essential for real world evidence generation. We describe utilization of an oncology clinical data program integrated with claims data to describe treatment patterns and outcomes.

Objective:

Evaluate treatment patterns, resource utilization, and total costs among metastatic triple negative breast cancer (TNBC) patients using linked clinical and claims database.

Methods:

Commercial patients with metastatic TNBC at diagnosis from February 2016 to May 2018 onwards with both clinical information from a Prior Authorization (PA) tool, based on NCCN guidelines, and claims from the Optum Research Database were selected to be included in the analysis. Demographics, clinical information (HER2 status, hormone status, metastatic status, and treatment line), treatment duration, resource utilization, and total cost were collected and uploaded to a dynamic web-based Tableau® dashboard. All cost data was adjusted to 2017 values.

AMCP Foundation Best Poster Awards are presented with:

CVSHealth

Results:

357 TNBC patients were identified; 213 (60%) were in their first line of therapy. 48% of the population was at least 55 years in age. The top five observed first line regimens accounted for 76% of patients: cyclophosphamide + doxorubicin (25%), carboplatin/cisplatin + gemcitabine (24%), paclitaxel (14%), paclitaxel protein-bound (8%), and carboplatin/cisplatin + paclitaxel (5%). The average duration of line 1 therapy was 76.2 days (median: 57 days); 80% of all patients had non-censored first lines. 41 patients (19%) had at least 1 inpatient stay during their first line. The average total cost for first line therapy was $50,087 (SD: $56,111). An additional 144 patients were in line 2+ at the first encounter in the PA data, the top 3 most common non-first line treatment regimens accounted for 49% of episodes: carboplatin/cisplatin + gemcitabine (19%), eribulin mesylate (18%), and paclitaxel protein-bound (12%). The average duration of line 2+ therapy was 91.1 days; and 118 (82%) were non-censored. 37 (26%) patients had 1+ inpatient stay during the line. The average total cost of non-first line therapy was: $56,310 (SD: $62,768).

Conclusions:

As the treatment lines progress, duration and costs increase by 20% and 12% respectively. Combination of clinical and claims based data points are valuable to evaluate treatment outcomes in specific personalized sub cohorts of patients and maybe one day used for treatment selection at individual lines of therapy.

Trends in Health Care: Expedited Drug Approvals

Breanna Popelar, PharmD, MS, Assistant Director, Strategic Market Access & Intelligence, Xcenda

Among the certainties in health care is the constant pace of change and intensity. Encouraging healthcare advancements that address unmet medical need while simultaneously ensuring product efficacy and patient safety is no small feat, especially when time is of the essence. This talk will explore perceptions from various healthcare stakeholders on expedited drug approval including challenges and opportunities. This research was conducted jointly by the AMCP Foundation and Xcenda, with sponsorship from Pfizer, Inc.

The Use of Real-World Endpoints in Cancer Drug Development

Jeff Allen, PhD, President and CEO, Friends of Cancer Research

Recent advancements to discover and develop targeted therapies, immunomodulating agents, and cell-based therapy provide new and potentially transformative opportunities for patients. In many ways, a new frontier of innovative therapies requires different tactics for developing, regulating, and evaluating cutting-edge care. Friends of Cancer Research, a Washington DC policy and advocacy organization, develops innovative partnerships aimed to accelerate the pace translating new discoveries into safe and effective therapies to treat cancer. This includes an ongoing collaborative research partnership is exploring the use of real-world evidence and new endpoints to assess outcomes of new cancer treatments over time.

Access, Affordability and Equity—The Impact of Cost of Care and Financial Toxicity

Gwen Darien, Executive Vice President for Patient Advocacy and Engagement,
National Patient Advocate Foundation

Building a health care system that delivers truly patient-centered care requires system change that is built upon the needs and experiences of patients and their caregivers. People facing serious illness and disability have always had to contend with the financial impact of their care on their lives. Those who have no insurance or are under-insured have suffered the highest level of financial toxicity, but people of all socioeconomic backgrounds feel the effects of the costs of their care. Mounting medical bills, increasing copays and cost sharing and the emergence of more effective but high-priced treatments for many conditions all contribute to the financial burden. Costs-of-care influences decisions about treatment, but also has a significant impact on the lives of patients and their families. It is not unusual for people to have to choose between buying groceries or paying for their medical care. Using patient experience data, both qualitative and quantitative, this session will explore the real-world impact of cost of care upon patient outcomes and experience and discuss best practices that drive cost of care conversations and solutions.

The Importance of Patient Experience Data: From Research to Survivorship

Elizabeth Franklin, MSW, Executive Director, Cancer Policy Institute, Cancer Support Community

A cancer diagnosis is an overwhelming experience, and cancer treatment is uniquely stressful for patients. Many practitioners and institutions view management of a patient's psychosocial experience, including mental health care assessments and interventions, to be a central part of providing cancer care for the whole patient. These practitioners recognize that negative psychosocial impacts are associated with increased levels of noncompliance with treatment protocols and follow-up, as well

as a poorer quality of life in patients with cancer. Emerging data supports this view, suggesting that measuring psychosocial impacts and providing appropriate care to cancer patients may result in better clinical outcomes, increased treatment adherence, and fewer/shorter hospital stays. This presentation will focus on the importance of collecting patient experience data from the design of clinical trials to the creation of survivorship care plans

Novel and Collaborative Approaches in Oncology RWD: Advancing Cancer Surveillance

Donna Rivera, PharmD, MSc, Scientific Project Officer, National Cancer Institute, NIH

Oncology data for observational research is dispersed across surveillance, clinical, and research enterprises along the cancer care continuum. NCI is developing and implementing new methods and initiatives to acquire, harmonize, aggregate, and analyze real world data (RWD). The NCI Surveillance, Epidemiology, and End Results (SEER) Program provides integrated population-based cancer reporting and represents 34% of the US population. Recognizing the changing paradigm in cancer care, SEER is enhancing the availability of detailed, longitudinal treatment data through collaborative partnerships across a variety of clinical data types (e.g. pharmacy, genomic, clinical). These data are necessary to evaluate the increasing use of immunotherapies and oral therapies, along with treatment outcomes such as adherence, ADEs, and recurrence outside of strictly maintained clinical trials. Advanced methods, interagency collaborations, and building a national data ecosystem can lead to enriched data for evaluating patient outcomes and care quality . As data shapes evidence-based care, pharmacists with clinical data science awareness are well-trained to fill an enhanced collaborative role in the development and delivery of leading-edge cancer care.

AI: Achieving and Utilizing its Potential

Petra Schultz, Pharm D, Associate Chief Health Officer, IBM Watson Health

Health data are growing at an exponential rate, and technologies in the workplace are advancing rapidly. There's a great deal of talk about the potential of artificial intelligence (AI) to make sense of big data; help patients, clinicians and healthcare leaders make better decisions; and revolutionize healthcare. In this session, we will review scientific evidence on the impact of solutions in healthcare today and how emerging technologies may be applied in the future.

Revolutionizing Health Care by Individualizing Patient Care

Joga Gobburu, PhD, MBA, FCP, Co-founder and Professor Director, Pumas-AI and Univ. MD School of Pharmacy

Despite the approval of new treatments in the US based on rigorous testing in patients, the therapeutic success rate in the clinic is 50-50. The reasons for this abysmal rate is that the trials test whether patients respond on an average; and there is no data on comparative effectiveness. With the advent of electronic medical records (EMR), valuable experience from millions of patients is now available for us to learn from and apply to improve the treatment trajectory for each patient. Pumas-AI, a company founded by University of Maryland, Baltimore researchers is developing clinical decisions support systems to aid HCPs to individualize treatments. The scope and progress made on this important initiative will be presented at this conference.

SPEAKERS

Jeff Allen, PhD

President and CEO, Friends of Cancer Research (Friends)

During the past 20 years, Friends has been instrumental in the creation and implementation of policies ensuring patients receive the best treatments in the fastest and safest way possible.

As a thought leader on many issues related to Food and Drug Administration, regulatory strategy and healthcare policy, he is regularly published in prestigious medical journals and policy publications, and has contributed his expertise to the legislative process on multiple occasions.

Recent Friends initiatives include the establishment of the Breakthrough Therapies designation and the development of the Lung Cancer Master Protocol, a unique partnership that will accelerate and optimize clinical trial conduct for new drugs. Dr. Allen received his Ph.D. in cell and molecular biology from Georgetown University, and holds a Bachelors of Science in Biology from Bowling Green State University.

Stacey DaCosta Byfield, PhD, MPH

Director of Research, UnitedHealth Group Research and Development

Dr. DaCosta Byfield, currently serves as a Director of Research within the UHG Research and Development group and is involved in developing strategies to identify and promote more cost effective interventions. Previously, Stacey served as the Vice President of Research for HEOR, where she oversaw the researcher teams responsible for conducting observational research studies using administrative claims, EHR/medical record data and other secondary data sources, as well as studies utilizing primary data collection methodologies. Prior to joining Optum, she worked in the Department of Drug Use Policy and Pharmacoeconomics at the University of Texas M.D. Anderson Cancer Center as a Pharmacoeconomics Research Specialist. In this capacity, her main responsibilities included developing research designs to evaluate clinical, economic and humanistic outcomes of pharmaceutical products and services. She holds a PhD in Tumor Biology from Georgetown University and completed a basic science fellowship at the National Cancer Institute where her work focused on identifying targets of pharmaceutical intervention for metastatic breast cancer. Dr. Dacosta Byfield also received her MPH with a concentration in clinical effectiveness from the Harvard T. H. Chan School of Public Health and has completed the Program in Cancer Outcomes Research Training (PCORT) Fellowship, a jointly sponsored program by the Massachusetts General Hospital and the Dana-Farber Harvard Cancer Center in Boston, Massachusetts. Dr. DaCosta Byfield has been an author or co-author in numerous peer-reviewed journals including Journal of Oncology Practice, Journal of Managed Care Specialty Pharmacy, American Journal of Clinical Oncology, American Journal of Gastroenterology, Archives of Dermatology Research, BJU International, Journal of Cancer Therapy, Journal of Cell Science, Journal of Neuro Oncology, Cancer Research, Melanoma Research and Molecular Pharmacology.

Kim A. Caldwell, RPh

Principal, Texas Star Healthcare Consulting, LLC

With more than four decades of experience within the complex and often disparate world of pharmaceutical health benefits and coverage, the last 10+ years with Humana, Inc., Mr. Caldwell chose to refocus priorities toward assisting others through independent consulting. His client base ranges from developer to payer, provider to patient, investor to legal to regulator, in domestic as well as international organizations.

In his role as Vice President for Humana's Pharmacy Professional Affairs, Kim led two unique business functions. One of his teams served to liaison between HPS business owners, Humana Public Affairs, and key professional and trade partners as the pharmacy subject matter experts for key business, legislative, and regulatory issues. His second group, Humana's evidence-based research team of which he was the founding member, helped influence focus on key healthcare questions in collaboration with selected private, public, and internal partners.

Mr. Caldwell is most recognized by many for his work helping to lead the development

and implementation of Part D – the Medicare prescription drug benefit. During 2004-2005, Kim served the Centers for Medicare and Medicaid Services (CMS) as Division Director - Clinical and Economic Performance in the Center for Beneficiary Choices (CBC).

He has extensive experience throughout the practice of pharmacy ranging from owner/operator of a small independent pharmacy to senior leadership positions within health plans and PBMs. Among other opportunities, Kim has worked in long-term care consulting, electronic prescribing, and the pharmaceutical industry. In addition to his work with CMS, Mr. Caldwell's professional service through government includes more than 12 years on the Texas State Board of Pharmacy.

Mr. Caldwell has received various honors and awards from his peers including the 2018 Steven G. Avey Award from the AMCP Foundation and the 2018 Next-Generation Pharmacist Lifetime Achievement Award from Parata/*Pharmacy Times*. Kim has also been honored to receive the 2010 Distinguished Service Award from AMCP. Mr. Caldwell served as President of AMCP, 2013-2014.

Michelle Chang, PharmD

Clinical Director, CVS Health

Presently serving as Clinical Director at CVS Health, Michelle began her career with the company as a PGY1 Managed Care Pharmacy Resident. She is expert in formulary management and has generated step therapy and utilization management guidelines for benefits. She also worked at Kaiser Permanente, Greater Baltimore. She received a PharmD from University of Maryland Baltimore and an MBA from the Merrick School of Business, University of Baltimore. She is a registered pharmacist in Maryland and Texas.

CVS Health is the funding partner for the AMCP Foundation Best Poster Competition and Awards, and a corporate member of AMCP. Headquartered in Woonsocket, RI, CVS Health is the largest pharmacy health care provider in the U.S. CVS Health is a health care innovation company with a simple and clear purpose: Helping people on their path to better health.

Gwen Darien

Executive Vice President for Patient Advocacy and Engagement, National Patient Advocate Foundation

Gwen Darien is a longtime patient advocate who has played leadership roles in some of the country's preeminent nonprofit organizations. As Executive Vice President for patient advocacy and engagement at the National Patient Advocate Foundation and the Patient Advocate Foundation, Gwen leads programs that link PAF's patient service programs to NPAF initiatives, with the goal of improving access to equitable, affordable, quality health care.

As a three-time cancer survivor herself, Gwen came into cancer advocacy expressly to change the experiences and outcomes for the patients who came after her and to change the public dialogue about cancer and other life-threatening illnesses. She started the first stand-alone advocacy entity in a professional cancer research organization at the American Association for Cancer Research where she launched CR magazine. Later, she served as executive vice president of programs and services at the Cancer Support Community. In each role, Gwen championed placing patients at the center of health system change, whether it is for research, public policy or direct services.

Gwen serves chair or on the board of a wide range of program committees and workshop faculties, including the Community Engagement in Genomics Working Group of the National Human Genome Research Institute and the Patient Engagement Advisory Panel for PCORI. Gwen also blogs about her experiences for US News & World Report. Gwen is a graduate of Sarah Lawrence College, where she also served as an advisor for their Health Advocacy program.

Elizabeth Franklin, MSW

Executive Director, Cancer Policy Institute, Cancer Support Community

Elizabeth Franklin, MSW, is Executive Director of the Cancer Policy Institute (CPI) at the Cancer Support Community (CSC). CSC is the largest provider of social and emotional support services for cancer

patients and their loved ones in the United States. The CPI brings together patient advocates and policy experts to ensure that the voices of cancer patients and their loved ones play a central role in federal and state legislative, regulatory, and executive policy making.

The CPI works in partnership with patient advocates, the CSC affiliate network, and numerous allied health care and oncology organizations to work towards a future where 15.5 million cancer survivors have access to comprehensive, high-quality, timely, and affordable medical, social, and emotional care. Elizabeth is responsible for all aspects of the CPI including legislative, regulatory, policy, and research priorities as well as operations, fundraising, and management. Elizabeth was previously Senior Director of Policy and Advocacy at CSC.

As former Director of Policy and Engagement at the George Washington University Cancer Institute, Elizabeth worked at both the macro level, developing and implementing the Institute's policy agenda, and at the micro level, working with the patient-centered care team to ensure that all patients had access to high-quality, timely cancer care. Previously, Elizabeth was Senior Director of Policy and Advocacy with the Prevent Cancer Foundation as well as Special Assistant to the Chief Executive Officer at the headquarters of the National Association of Social Workers.

Elizabeth is a recognized author and speaker. Her articles have appeared in publications such as *Value in Health*, *Journal of Clinical Pathways*, *Journal of Cancer Education*, *Health and Social Work*, and *Conquer Cancer* Magazine. She has co-authored two books on non-profit leadership and co-edited two social work texts.

Currently a doctoral candidate at the University of Maryland School of Social Work, Elizabeth is focusing her dissertation on the ways in which patients define value in the cancer care system and how those definitions can be incorporated into public policy and clinical practice. Elizabeth obtained her Master's Degree in Social Work from the University of Illinois at Chicago and her Bachelor's Degree in Social Work from the University of Kentucky.

Paula J. Eichenbrenner, MBA, CAE

AMCP Foundation Executive Director

Paula J. Eichenbrenner was appointed Executive Director of the Academy of Managed Care Pharmacy (AMCP) Foundation in November 2015. In this capacity, she partners with the Board of Trustees to provide strategic leadership for the AMCP Foundation, which advances critical insights and develops leaders. Eichenbrenner also serves on the Foundation Board as Secretary and Trustee ex officio.

Prior to joining the AMCP Foundation, Ms. Eichenbrenner held leadership roles at the American Society for Nutrition/ASN Foundation and the Council for Affordable and Rural Housing. She has been recognized with numerous industry distinctions, including the *Association Trends* Young & Aspiring Association Professional Award.

Paula has contributed presentations, scientific posters, articles, interviews and other thought pieces in health care, pharmacy, nonprofit management and business settings and publications. Eichenbrenner is a Certified Association Executive (CAE) with fundraising and public affairs experience in diverse non-profit settings including trade associations, professional societies and foundations. She holds a Master's in Business Administration (MBA) with a specialization in global business from Virginia Tech, and is an honors graduate of Tulane University.

Ms. Eichenbrenner is a member of the Association Foundation Group (where she serves as Treasurer on the Board of Directors) and the Association of Fundraising Professionals. Her professional affiliations also include the American Society of Association Executives, where she is a past committee chair. Additionally, Paula serves on the Newcomb College Institute Director's Advisory Council. In 2019, she received the Young Alum of the Year Award from the Newcomb College Alumni Association of Tulane University.

Joga Gobburu, PhD, MBA

Professor, Executive Director, Center for Translational Medicine, Schools of Pharmacy & Medicine, University of Maryland; Founder, Pumas-AI

Dr. Gobburu is a Professor with the School of Pharmacy, University of Maryland, Baltimore, MD, USA. He held various positions at the US FDA between 1999 and 2011. Under his leadership, a Division of Pharmacometrics was formed at the FDA and several policies were established. Dr. Gobburu is a co-founder of Pumas-AI, a company committed to developing point-of-care solutions for providers and clinicians that can help individualize treatment for patients.

Breanna Popelar, PharmD, MS

Assistant Director, Strategic Market Access & Intelligence, Xcenda

Breanna Popelar, PharmD, MS, is an Assistant Director on the Strategic Market Access and Insights team at Xcenda. Her work in this role spans a variety of projects including value proposition development, market access strategy, and payer market research. Dr. Popelar also has expertise in Global Health Economics and Outcomes Research (GHEOR) including staffing solutions engagements and GHEOR strategy. She is passionate about evidence-driven healthcare and utilizes her clinical knowledge and economic background to drive access and inform decisions in an increasingly complex market.

Prior to joining Xcenda in 2013, Dr. Popelar's experiences included working at Coventry Health Care, the Los Angeles County Department of Health Services, a comprehensive cancer center, and a major integrated health care delivery system.

Dr. Popelar earned her Doctor of Pharmacy degree from the University of Southern California and her Bachelor of Science degree in Applied Economics and Biochemistry from the University of the Pacific. She also completed a 2-year fellowship in Health Outcomes and Managed Markets at Xcenda and holds a Master of Science degree in Applied Pharmacoeconomics from the University of Florida.

Karen L. Rascati, RPh, PhD

Karen L. Rascati, RPh, PhD, Assistant Editor, *Journal of Managed Care and Specialty Pharmacy*

Karen L. Rascati, RPh, PhD, is also the Graduate Advisor for the College of Pharmacy. Dr. Rascati has supervised over 60 MS and PhD graduate student projects and has authored or co-authored more than 140 publications (including many textbook chapters and two editions of her textbook *Essentials of Pharmacoeconomics*) and over 250 national/international meeting presentations. Her research interests include economic and outcomes evaluations for several disease states as well as for pharmacy services. She has conducted over 40 funded research projects and served on various grant review panels. She is a Fellow of the American Pharmacist Association (FAPhA), has served as President of the Rho Chi National Honor Society, and on the Board of Directors (Treasurer) of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). She is currently faculty advisor for the University of Texas student chapter of AMCP. Much of her research is analyzing large health care databases.

Donna R. Rivera, PharmD, MSc

Scientific Project Officer and Pharmacist, Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute

Donna Rivera, PharmD, MSc, is a pharmacist and pharmacoepidemiologist focused on the generation of real world evidence for targeted cancer therapies to guide clinical decision-making and improve the quality of cancer patient care delivery.

In her current role as a Scientific Project Officer with the Surveillance Research Program in the Division of Cancer Control and Population Sciences at the National Cancer Institute (NCI), she leads a strategic real world data initiative which evaluates, designs, and facilitates large scale heterogenous data linkages with the SEER program to enhance the availability of longitudinal treatment data.

She is responsible for developing collaborative partnerships across several federal agencies, including the VA, CDC, FDA, and DOE, as well as academic institutions and commercial entities to advance research in the strategic areas of precision cancer surveillance and novel linkage methods.

Dr. Rivera's research focuses on the use of pharmacoepidemiology and pharmacosurveillance to evaluate medication utilization and health outcomes at the patient and population level across the changing cancer treatment landscape, with an emphasis on targeted oral agents, immunotherapies, and vaccines.

Dr. Rivera earned her Doctor of Pharmacy and Master of Science in Pharmaceutical Sciences with a concentration in Pharmaceutical Outcomes and Policy from the University of Florida College of Pharmacy. She completed a postdoctoral fellowship in Pharmacoepidemiology and Pharmacogenomics at the NCI in the Epidemiology and Genomics Research Program. Prior to NCI, Donna worked on Phase I clinical trials at Stiefel, a GlaxoSmithKline company.

Petra Schultz, PharmD

Associate Chief Health Officer, IBM Watson Health

Dr. Schultz has 20 years experience in health care, focused in drug information, therapeutic policy management, and healthcare information technology. In her current role, Petra focuses on translating the scientific evidence behind IBM Watson Health solutions and services to support the business in leading with science when speaking the value of Watson Health solutions. Since joining then Thomson Healthcare in 2006, Petra has held several roles, including content development, clinical specialist support, and product management for the Micromedex® clinical decision support portfolio.

Petra received her Bachelor of Science degree in Marketing from Florida State University and her Doctor of Pharmacy degree from the University of Florida followed by completion of residencies in Pharmacy Practice and Drug Information Practice at University Medical Center (Jacksonville) and Shands Jacksonville, now a part of UF Health. Earlier in her career, she practiced and held academic appointments in drug information and therapeutic policy management at the Medical University of South Carolina and the Mayo Clinic Florida.

Petra's personal interests include travel, hiking, skiing, yoga, and appreciation of all kinds of music. She comes from a family of musicians and is currently enjoying participating in a 3-year foundational music course with her 7-year-old son.

Harpreet Singh, MD

Team Leader, Breast Cancer Drug Development, Food & Drug Administration

Dr. Singh is a Medical Oncologist at the FDA, and currently serves as a Team Leader in Breast Cancer Drug Development. She continues to see patients at the National Cancer Institute. Dr. Singh is a native of Los Angeles, California and graduated from the University of California, San Diego before completing her medical degree at the University of Southern California Keck School of Medicine. She completed her internal medicine residency and geriatrics fellowship at the Los Angeles County + University of Southern California Medical Center.

Dr. Singh then went on to the National Cancer Institute at the National Institutes of Health for a fellowship in Medical Oncology. She focused on tumor immunology and biology, including cancer vaccines and immunotherapy clinical trials. Dr. Singh joined the FDA as a Medical Officer in 2015.

With a strong interest in geriatric oncology, Dr. Singh is currently the Scientific Liaison for Cancer in Older Adults, and has presented research at major conferences, including the American Society for Clinical Oncology and the American Society for Hematology. Dr. Singh is an active member of the Cancer and Aging Research Group, a dynamic group of geriatric oncology researchers across the nation who work to in a collaborative effort to design and implement clinical trials to improve the care of older adults with cancer. She has been working actively with ASCO and other key stakeholders to increase the evidence base for treating older adults with cancer.



Peter Wehrwein

Symposium Moderator
Editor-in-Chief,
Managed Care Magazine

Wehrwein has been editor of *Managed Care* since January 2015. As editor, he oversees the content of the monthly print publication, email newsletters, and the magazine's website. He is also currently serving as editor of a sibling publication, P&T. Before editing *Managed Care*, Wehrwein was editor of the Harvard Health Letter, a monthly consumer health newsletter published by Harvard Medical School. Prior to the Health Letter, he was editor of the Harvard Public Health Review, published by the Harvard T.H. Chan School of Public Health. He was journalism fellow at the school in 1993–94. Wehrwein has written for Cancer Discovery, Nature, Lancet, Nova Next, Newsweek, and a number of other publications. He began his career in newspapers and was a staff reporter for the Albany Times Union and papers in New Jersey, Brooklyn, and Minnesota. He lives in the Mt. Airy section of Philadelphia.

SAVE THE DATE!

5K RUN FOR THE FUTURE
SEVENTH ANNUAL
HOUSTON, TEXAS

Thursday, April 23
at **AMCP**2020

Thank you, Alkermes.

Board of Trustees | 2019–2020

PRESIDENT
Christopher V. Goff, Esq.

VICE PRESIDENT
Kathleen Moreo, RN, BSN, CCM, Cm, CDMS

TREASURER
Alan J. Arville, Esq.

SECRETARY
Paula J. Eichenbrenner, MBA, CAE

TRUSTEE
Allan J. Chernov, MD

TRUSTEE
Jan E. Hansen, PhD



TRUSTEE
Matthew W. Hurlburt, MHA

TRUSTEE
Summerpal Kahlon, MD

TRUSTEE
Susan Shiff, PhD, MBA

TRUSTEE
Annesha White, MS, PhD

TRUSTEE
Mary C. Young, MHPA, CEBS

CHAIR
Susan A. Cantrell, RPh, CAE
AMCP CEO

Data Drivers Fostering Innovations in Oncology

AMCP and AMCP Foundation Resources

AMCP *Journal of Managed Care & Specialty Pharmacy*, Volume 24, Issue 6, June 2018

AMCP Partnership Forum Proceedings - Driving Value and Outcomes in Oncology

- www.jmcp.org/doi/full/10.18553/jmcp.2018.24.6.572

AMCP *Journal of Managed Care & Specialty Pharmacy*, Volume 25, Issue 2, February 2019

Current and Future Oncology Management in the United States

- www.jmcp.org/doi/full/10.18553/jmcp.2019.25.2.272

AMCP Foundation Webinar, Trends in Healthcare: Artificial Intelligence and Tech, May 2019

- www.amcpfoundation.org/node/1216/

Other Resources

Forbes Insights, Issue 4, AI and Healthcare: A Giant Opportunity, February 2019

- www.forbes.com/sites/insights-intelai/2019/02/11/ai-and-healthcare-a-giant-opportunity/#5bda95cc4c68

IBM Watson Health in Oncology Portfolio 2019

- www.ibm.com/downloads/cas/0ZRYPWL9

AMA Journal of Ethics, Ethical Dimensions of Using Artificial Intelligence in Healthcare, February 2019

- journalofethics.ama-assn.org/article/ethical-dimensions-using-artificial-intelligence-health-care/2019-02

Health IT Analytics Blog, How Healthcare Can Prep for Artificial Intelligence, Machine Learning, October 2016

- healthitanalytics.com/features/how-healthcare-can-prep-for-artificial-intelligence-machine-learning

CB Insights Tech Market Intelligence Platform, The AI Industry Series: Top Healthcare AI Trends to Watch

- www.cbinsights.com/research/report/ai-trends-healthcare/

The Wall Street Journal, The Ethical Dilemmas AI Poses for Healthcare, October 2019

- www.wsj.com/articles/the-ethical-dilemmas-ai-poses-for-health-care-11571018400?mod=searchresults&page=1&pos=1

Oncology Times, How Artificial intelligence is Changing Oncology, November 2018

- journals.lww.com/oncology-times/Fulltext/2018/11050/How_Artificial_Intelligence_Is_Changing_Oncology.7.aspx

Friends of Cancer Research, Pink Sheet-External Control Arms: Better Than Single-Arm Studies But No Replacement for Randomization, January 2019

- www.focr.org/news/pink-sheet-external-control-arms-better-single-arm-studies-no-replacement-randomization

STAT Blog, Synthetic Control Arms Can Save Time and Money in Clinical Trials, February 2019

- www.statnews.com/2019/02/05/synthetic-control-arms-clinical-trials/

Data Drivers Fostering Innovations in Oncology

Other Resources (continued)

Centers for Disease Control and Prevention, Division of Care Prevention and Control, National Program of Cancer Registries, July 2018

- www.cdc.gov/cancer/npcr/value/registries.htm

Health Affair Blog, Health Information Exchange After 10 Years: Time for a More Assertive, National Approach, August 2019

- www.healthaffairs.org/do/10.1377/hblog20190807.475758/full/

Clinical Research News, The Intelligent Trial: AI Comes to Clinical Trials, September 2017

- www.clinicalinformaticsnews.com/2017/09/29/the-intelligent-trial-ai-comes-to-clinical-trials.aspx

MIT-based Financing and Reimbursement of Cures in the US Consortium recommendations

Federal Policy Suggestions for Durable Therapies, February 2019

- www.payingforcures.org/2019/wp-content/uploads/2019/02/P4C-Policy-Recommendations.pdf

JNCCN Journal, Volume 17, Number 5, Policy Challenges and Opportunities to Address Changing Paradigms in Cancer Care Delivery, May, 2019

- jnccn.org/view/journals/jnccn/17/5/article-p424.xml

Wolters Kluwer White Paper, Harnessing the Power of Data to Advance Value-Based Care, May 2019

- https://tinyurl.com/DataVBC

ASCPT Journal, Volume 106, Issue 1, Pages 60-66, June 2019

Harnessing the Power of Collaboration and Training Within Clinical Data Science to Generate Real-World Evidence in the Era of Precision Oncology

- ascpt.onlinelibrary.wiley.com/doi/abs/10.1002/cpt.1459

FDA Archives, *Pfizer Oncology, Real World Pragmatic Studies*: Pharma Perspective and a Recent Example, November 2017

- https://tinyurl.com/RWPharma

AMCP Foundation

EVENTS

RESEARCH SYMPOSIUM & BEST POSTER AWARD

Tuesday, October 29 | 1:00 pm – 5:00 pm
Cherry Blossom Ballroom
Posters are in The Exchange, Prince George AB

Our 9th Annual Symposium is focused on technology and treatment decision-making in oncology. Experts will explore challenges of data, value, and optimal health care coverage from the perspectives of shared decision-making, payer and health plans and industry use of HIT/AI to advance research, accelerate regulatory approvals and communicate value. See page 9 for details.

Thank you, Amgen and Merck.

SLEEP-IN FOR WELLNESS FUNDRAISER

Want to support the Foundation without an early-morning wake-up call? Ask for the **Sleep-In for Wellness option** and we won't enroll you in Sunrise Yoga — but you can still pick up an AMCP Foundation Means Well(ness) T-shirt at registration. *$20 donation, inquire at registration.*

SUNRISE YOGA CLASSES

Wednesday, October 30 | 6:00 am – 7:00 am
Thursday, October 31 | 6:00 am – 7:00 am
Azalea 1

"Sweatworking" — networking designed to encourage healthy living on the road! Led by certified instructors and suitable for fitness enthusiasts or yoga practitioners at all levels. All yogis receive an AMCP Foundation Means Well(ness) T-shirt. *$20, inquire at registration.*

SP2: IDENTIFYING AND EVALUATING INFORMATION FOR EVIDENCE-BASED DRUG FORMULARIES

Thursday, October 31 | 10:00 am – 11:30 am
National 10–11

Attend this session to learn about best practices for formulating a clinical question, performing literature searches, and evaluating evidence to synthesize into a drug monograph. Along with the AMCP Student Pharmacist Committee, we particularly encourage attendance by team members, student chapter leaders, and advisors involved with AMCP Foundation's National P&T Competition.

held in conjunction with AMCP NEXUS 2019

Visit posters during author presentations on **Thursday, beginning at 12:30 pm**, to view AMCP Foundation Summer Intern posters.

The Foundation Poster Mentors will also be in action and we will select additional recipients for Best Poster Awards—presented with CVS Health.